Recruiting

Testing a new combination therapy for recurring ovarian cancer

Plain-English translation of NCT07714668 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated October 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new drug called SYS6041 in combination with other well-established ovarian cancer medications to see if it works better and is safe for people whose ovarian cancer has returned. Researchers will try different combinations of this medication with standard treatments like chemotherapy and bevacizumab (a drug that stops blood vessel growth in tumors). The goal is to find out whether adding this new treatment helps control recurrent ovarian cancer and improves outcomes for patients.

Ovarian cancer that comes back after initial treatment is very difficult to manage, and current options don't work well enough for everyone. This trial exists to see if this medication might offer a better chance of controlling the cancer when combined with treatments already known to help.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after treatment
your cancer is considered platinum-sensitive (responds to certain chemotherapy drugs) or platinum-resistant, depending on which group enrolls you
you have received no more than 2–3 prior lines of chemotherapy, depending on your cancer type
your overall health is good enough to handle treatment, with an ECOG performance status of 0–1
you are expected to live at least 3 months

You likely don't qualify if…

you have previously received a topoisomerase I inhibitor-loaded antibody-drug conjugate therapy
you have had another cancer diagnosed within the past 3 years (except for certain easily treated skin or bladder cancers)
you have cancer that has spread to your brain and requires ongoing treatment or steroids
you have severe heart disease, severe stomach or bowel problems, or a history of lung inflammation
you are currently taking certain medications that strongly interact with this new drug

What participation looks like

You will receive the new medication SYS6041 in combination with other ovarian cancer drugs (such as chemotherapy or bevacizumab, depending on which treatment group you are assigned to) in 3-week cycles. You will continue treatment as long as the cancer does not progress, you do not experience unmanageable side effects, or you decide to stop. Throughout the study, your doctors will monitor how well the treatment works and check for any side effects through regular visits and blood tests.

AI-generated summary from trial data · Oct 22, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality